Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other financing activities (2019 - 2024)

Summit Therapeutics (SMMT) has disclosed Other financing activities for 4 consecutive years, with $80000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Other financing activities changed N/A year-over-year to $80000.0, compared with a TTM value of $80000.0 through Mar 2024, down 86.28%, and an annual FY2023 reading of $619000.0, up 1306.82% over the prior year.
  • Other financing activities was $80000.0 for Q2 2023 at Summit Therapeutics, down from $539000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $539000.0 in Q1 2023 and bottomed at -$67000.0 in Q4 2022.
  • Average Other financing activities over 4 years is $176666.7, with a median of $95500.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 204.69% in 2022, while the deepest fall reached 204.69% in 2022.
  • Year by year, Other financing activities stood at $333000.0 in 2019, then crashed by 80.78% to $64000.0 in 2021, then plummeted by 204.69% to -$67000.0 in 2022, then soared by 219.4% to $80000.0 in 2023.
  • Business Quant data shows Other financing activities for SMMT at $80000.0 in Q2 2023, $539000.0 in Q1 2023, and -$67000.0 in Q4 2022.